AFMD News and Press, Affimed N.V. From 01/08/24

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR- wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort Follow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still aw...

2024-01-08 08:30:29 ET More on Affimed Affimed N.V. (AFMD) Q3 2023 Earnings Call Transcript Affimed N.V. 2023 Q3 - Results - Earnings Call Presentation Affimed sells AbCheck unit for $6M Affimed drops on plans to discontinue enrollment for cancer study cohort...

Dr. Adi Hoess to step down as CEO and Management Board Member Dr. Andreas Harstrick appointed Interim CEO Strategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025 Go forward organization will focus on advancing clinical programs Company confirms ...

2024-01-03 06:44:04 ET Immuno-oncology company Affimed ( NASDAQ: AFMD ) announced on Wednesday a deal to sell its wholly-owned subsidiary, AbCheck. Founded in 2009 as a spin-out of Affimed's antibody technology discovery unit, AbCheck discovers and optimizes human antibo...

MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definit...

2023-12-19 09:08:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors...

2023-12-11 08:35:07 ET Affimed ( NASDAQ: AFMD ) shares erased premarket gains despite reporting encouraging data on its lead innate cell engager ( ICE ) acimtamig in patients with recurrent or refractory Hodgkin lymphoma patients who failed prior chemotherapy. Phase 1/2 ...

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC) expansion cohort Responses observed in 4 of 15 patients, including 1 confirmed partial response (PR), 1 unconfirmed complete response ...

In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose level (RP2D), the objective response rate (ORR) was 97% and the complete response (CR) rate was 78% In this cohort median EFS was 9.8 months with 84% patients alive at 12 months, and me...

Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203 Review clinical data for AFM24 in solid tumors Conference call/webcast on Monday, December 11, 2023 at 1:30 p.m. PST / 4:30 p.m. EST / 22:...